Priority review your cooked


Net sales in the Specialty Pharmaceuticals segment for the first quarter of fiscal 2014 were $309.5 million, an increase of 18.9%, compared with $260.2 million in the prior-year period. Operational growth was 19.1%. Net sales in Brands were $59.6 million, compared with $46.6 million last year, led by net sales from EXALGO(R) (hydromorphone HCl) Extended-Release Tablets, CII. Net sales in Generics and Active Pharmaceutical Ingredients (API) were $249.9 million, compared with $213.6 million last year, primarily driven by net sales from Methylphenidate HCl Extended-Release Tablets, USP CII (Methylphenidate ER) and the net benefit from pricing actions on certain specialty generics products.

Where are you getting $230 million?. Actavis generic approved but not available yet (or only recently)?

Can't explain 2013 results for first 2 quarters of 2014.

Click on the link and read this paragrap-

"Exalgo® is indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. For the 12 months ending February 28, 2014, Exalgo® had total U.S. sales of approximately $230 million, according to IMS Health data."

http://www.actavis.com/news/news/thomson-reuters/actavis-receives-final-approval-for-generic-versio
 

I stand corrected. But $230 mil aint so hot either. Opana ER was doing north of 400 mil.

http://www.zacks.com/stock/news/109757/Generic-Product-Launches-at-Actavis

Well good luck getting zohydro to do that good. Obviously you are just now getting your education in the pain mkt. I'm done with this waste of time. Next time you go bagging on competitors products try not to reveal yourself to be such a dumba$$.
 


Write your reply...